Dr. Stuart Weinerman, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,771
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
NY license 166011
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
Medical groups
- North Shore-Lij Medical PC (6,440 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,771
- Services billed
- 165,008
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 88,260 | 859 |
| Injection, romosozumab-aqqg, 1 mg | 45,150 | 45 |
| Injection of drug or substance under skin or into muscle | 1,719 | 899 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,219 | 994 |
| Dxa bone density measurement of hip, pelvis, spine | 1,004 | 990 |
| Established patient office or other outpatient visit, 20-29 minutes | 441 | 407 |
| New patient office or other outpatient visit, 45-59 minutes | 148 | 148 |
| Hemoglobin a1c level | 55 | 43 |
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in New Hyde PArk, NY | 524 |
| Alendronate Sodium Other prescribers in New Hyde PArk, NY | 361 |
| Risedronate Sodium Other prescribers in New Hyde PArk, NY | 354 |
| Ibandronate Sodium Other prescribers in New Hyde PArk, NY | 187 |
| Synthroid (levothyroxine sodium) Other prescribers in New Hyde PArk, NY | 185 |
| Prolia (denosumab) Other prescribers in New Hyde PArk, NY | 120 |
| Raloxifene Hcl Other prescribers in New Hyde PArk, NY | 109 |
| Metformin Hcl Other prescribers in New Hyde PArk, NY | 65 |
| Ozempic (semaglutide) Other prescribers in New Hyde PArk, NY | 45 |
| Risedronate Sodium Dr (risedronate sodium) Other prescribers in New Hyde PArk, NY | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $11,081 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of crinecerfont (NBI-74788) in adult subjects with classic congenital adrenal hyperplasia, followed by open-label treatment
Neurocrine Biosciences, Inc. - Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.